Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASTERN: Botulinum Toxin for Trigeminal Neuralgia
NCT03331913Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2017
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A in trigeminal neuralgia (TN) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Pain relief at 4 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT03331913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331913.